Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TR987 0.1%+ Standard of Care · 1 trial · 8 indications
Patient count
| Arm | Type | Description |
|---|---|---|
| TR987 0.1% gel + Standard of Care | EXPERIMENTAL | Participants will receive up to 16 weeks of TR987 0.1% gel topically + Standard of Care (wound cleansing/dressings and compression bandaging). Treatment will be twice weekly for the first four weeks then weekly for the remaining 12 weeks. |
| Standard of Care | OTHER | - |
| Name | Type | Description |
|---|---|---|
| TR987 0.1% gel + Standard of Care | DRUG | 6mg topical gel for application plus Standard of Care (wound cleansing/dressings and compression bandaging) |
| Standard of care | OTHER | Standard of Care (wound cleansing/dressings and compression bandaging) |
Inclusion Criteria: * Adults 18 years and older * Venous insufficiency has been clinically diagnosed clinically and medically confirmed. * Females who are neither pregnant nor breastfeeding and if of child-bearing potential are on an acceptable method of birth control. * The Venous Ulcer should be ...
TR987 0.1%+ Standard of Care is an investigational small molecule gel being studied for the treatment of venous leg ulcers, including venous stasis ulcers and non-healing wounds. It is administered as a 0.1% gel in combination with standard of care. The drug is currently in Phase 3 clinical development.
TR987 0.1%+ Standard of Care is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The company is conducting a Phase 3 clinical trial to evaluate the drug for venous leg ulcers.
TR987 0.1%+ Standard of Care is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 3 trial is recruiting participants in the United States.
TR987 0.1%+ Standard of Care is being evaluated in a Phase 3 clinical trial with the identifier NCT06707090. This randomized, double-blind, controlled study is enrolling 312 participants aged 18 years and older with venous leg ulcers in the United States.
Yes, TR987 0.1%+ Standard of Care is also known as TR987 0.1% gel + Standard of Care. Both names refer to the same investigational drug product being developed by cbdMD, Inc. for the treatment of venous leg ulcers.